SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer today announced that it will release its second quarter financial results on Thursday, August 5, 2020 after the market closes. Kezar’s executive team will host a conference call to discuss the company’s second quarter 2020 financial results and provide a general business update.
The conference call and webcast is scheduled for August 5, 2020 at 4:30 PM EDT. In order to participate in the conference call, please dial +1- 877-407-9711 (U.S.Toll-Free). An audio webcast and international dial-in numbers can be accessed under “News/Events” through the “Investors” section of the Kezar corporate website at www.kezarlifesciences.com. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days.
About Kezar Life Sciences
Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from Kezar’s protein secretion program, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com.